MoodCalmer™ for low mood depression
Cobalt Therapeutics, LLC offers products that fit seamlessly into current clinical settings and enhance their therapeutic offerings to patients, decrease costs, and improve outcomes.
These programs have been evaluated in randomized, controlled trials and published in leading peer-reviewed journals.
MoodCalmer™ is web-based and derived from an earlier program called COPE. In an open multi-site trial across two continents, COPE was shown to:
- Reduce depression severity by 41% in all participants enrolled.
- Reduce depression severity by 52% in completers.
- Have high levels of patient satisfaction with 68% completing the program.
The program helps users develop long-lasting improvements in depression by teaching them new cognitive and behavioral skills.